Assess Intermediate Force Capabilities (IFC) and concept of operations for application during the Competition Phase in an environment of GPC

NPS NRP Executive SummaryIntermediate force capabilities represent a strategic risk mitigation investment that are designed to provide warfighters tools to compete below the level of major armed conflict without losing credibility in the information. This research examines the effects of a set of intermediate force capabilities to assess the strategic impact on a near peer adversary during the competition phase in a 'gray zone' scenario. The effort will seek to gain insights and identify challenges to the employment of IFCs, through several venues, including leveraging defense analysis and operations research department faculty and students and utilizing the NPS warfighting continuum of Joint Campaign Analysis and Wargaming Applications courses.HQMC Plans, Policies & Operations (PP&O)This research is supported by funding from the Naval Postgraduate School, Naval Research Program (PE 0605853N/2098). https://nps.edu/nrpChief of Naval Operations (CNO)Approved for public release. Distribution is unlimited.

Assess Intermediate Force Capabilities (IFC) and concept of operations for application during the Competition Phase in an environment of GPC

NPS NRP Project PosterIntermediate force capabilities represent a strategic risk mitigation investment that are designed to provide warfighters tools to compete below the level of major armed conflict without losing credibility in the information. This research examines the effects of a set of intermediate force capabilities to assess the strategic impact on a near peer adversary during the competition phase in a 'gray zone' scenario. The effort will seek to gain insights and identify challenges to the employment of IFCs, through several venues, including leveraging defense analysis and operations research department faculty and students and utilizing the NPS warfighting continuum of Joint Campaign Analysis and Wargaming Applications courses.HQMC Plans, Policies & Operations (PP&O)This research is supported by funding from the Naval Postgraduate School, Naval Research Program (PE 0605853N/2098). https://nps.edu/nrpChief of Naval Operations (CNO)Approved for public release. Distribution is unlimited.

Assess Intermediate Force Capabilities (IFC) and concept of operations for application during the Competition Phase in an environment of GPC

NPS NRP Technical ReportIntermediate force capabilities represent a strategic risk mitigation investment that are designed to provide warfighters tools to compete below the level of major armed conflict without losing credibility in the information. This research examines the effects of a set of intermediate force capabilities to assess the strategic impact on a near peer adversary during the competition phase in a 'gray zone' scenario. The effort will seek to gain insights and identify challenges to the employment of IFCs, through several venues, including leveraging defense analysis and operations research department faculty and students and utilizing the NPS warfighting continuum of Joint Campaign Analysis and Wargaming Applications courses.HQMC Plans, Policies & Operations (PP&O)This research is supported by funding from the Naval Postgraduate School, Naval Research Program (PE 0605853N/2098). https://nps.edu/nrpChief of Naval Operations (CNO)Approved for public release. Distribution is unlimited.

Navy Force Structure Review Strategic Risk Workshop and Technology Review

NPS NRP Project PosterThe study's goal is to comparatively evaluate combat effectiveness of the planned Fleet Design with a novel alternative design against potential global adversaries in the 2040 timeframe. Insights and recommendations from the study will be used in the next Force Structure Assessment and the FY 2024 30-Year Shipbuilding Plan.N8 - Integration of Capabilities & ResourcesThis research is supported by funding from the Naval Postgraduate School, Naval Research Program (PE 0605853N/2098). https://nps.edu/nrpChief of Naval Operations (CNO)Approved for public release. Distribution is unlimited.

Navy Force Structure Review Strategic Risk Workshop and Technology Review

NPS NRP Executive SummaryThe study's goal is to comparatively evaluate combat effectiveness of the planned Fleet Design with a novel alternative design against potential global adversaries in the 2040 timeframe. Insights and recommendations from the study will be used in the next Force Structure Assessment and the FY 2024 30-Year Shipbuilding Plan.N8 - Integration of Capabilities & ResourcesThis research is supported by funding from the Naval Postgraduate School, Naval Research Program (PE 0605853N/2098). https://nps.edu/nrpChief of Naval Operations (CNO)Approved for public release. Distribution is unlimited.

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Deglobalization and National Security [video]

A Seapower Conversation presentationNaval Warfare Studies Institute (NWSI

MORS Workshop, Analytic Support for Maritime Domain Awareness and Counter-Piracy

PowerPoint Presentation of the MORS Workshop, Military Operations Research SocietyPurpose: to explore and identify ways in which operational research and analysis can support the MDA mission within the context of the open ocean